Education
About Us
Working with TipRanks
Follow Us
Spago Nanomedical AB (DE:7UX)
FRANKFURT:7UX
7UX Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.01 - €0.04
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€9.11M
Enterprise Value€67.78M
Total Cash (Recent Filing)€26.58M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Aug 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding348,196,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)3.69
Price to Sales (P/S)0.00
P/FCF Ratio-3.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
7UX FAQ
What was Spago Nanomedical AB’s price range in the past 12 months?
Spago Nanomedical AB lowest stock price was €0.01 and its highest was €0.04 in the past 12 months.
What is Spago Nanomedical AB’s market cap?
Spago Nanomedical AB’s market cap is €9.11M.
When is Spago Nanomedical AB’s upcoming earnings report date?
Spago Nanomedical AB’s upcoming earnings report date is Aug 20, 2025 which is in 30 days.
How were Spago Nanomedical AB’s earnings last quarter?
Currently, no data Available
Is Spago Nanomedical AB overvalued?
According to Wall Street analysts Spago Nanomedical AB’s price is currently Overvalued.
Does Spago Nanomedical AB pay dividends?
Spago Nanomedical AB does not currently pay dividends.
What is Spago Nanomedical AB’s EPS estimate?
Spago Nanomedical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Spago Nanomedical AB have?
Spago Nanomedical AB has 348,196,200 shares outstanding.
What happened to Spago Nanomedical AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Spago Nanomedical AB?
Currently, no hedge funds are holding shares in DE:7UX
Company Description
Spago Nanomedical AB
Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.
Technical Analysis
OncoZenge AB
―
Modus Therapeutics Holding AB
―
ExpreS2ion Biotech Holding AB
―
CombiGene AB
―
Bio-Works Technologies AB
―